{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:34:36Z","timestamp":1780112076826,"version":"3.54.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Drug repurposing for COVID-19 has several potential benefits including shorter development time, reduced costs and regulatory support for faster time to market for treatment that can alleviate the current pandemic. The current study used molecular docking, molecular dynamics and protein-protein interaction simulations to predict drugs from the Drug Bank that can bind to the SARS-CoV-2 spike protein interacting surface on the human angiotensin-converting enzyme 2 (hACE2) receptor. The study predicted a number of peptide-based drugs, including Sar9 Met (O2)11-Substance P and BV2, that might bind sufficiently to the hACE2 receptor to modulate the protein-protein interaction required for infection by the SARS-CoV-2 virus. Such drugs could be validated in vitro or in vivo as potential inhibitors of the interaction of SARS-CoV-2 spike protein with the human angiotensin-converting enzyme 2 (hACE2) in the airway. Exploration of the proposed and current pharmacological indications of the peptide drugs predicted as potential inhibitors of the interaction between the spike protein and hACE2 receptor revealed that some of the predicted peptide drugs have been investigated for the treatment of acute respiratory distress syndrome (ARDS), viral infection, inflammation and angioedema, and to stimulate the immune system, and potentiate antiviral agents against influenza virus. Furthermore, these predicted drug hits may be used as a basis to design new peptide or peptidomimetic drugs with better affinity and specificity for the hACE2 receptor that may prevent interaction between SARS-CoV-2 spike protein and hACE2 that is prerequisite to the infection by the SARS-CoV-2 virus.<\/jats:p>","DOI":"10.1371\/journal.pone.0245258","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T19:04:15Z","timestamp":1610132655000},"page":"e0245258","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2)"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7462-6669","authenticated-orcid":true,"given":"Samuel","family":"Egieyeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Egieyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0420-2916","authenticated-orcid":true,"given":"Sarel","family":"Malan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Christofells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burtram","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"pone.0245258.ref001","first-page":"1","article-title":"Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists March 2020","volume":"24","author":"D Thomas-R\u00fcddel","year":"2020","journal-title":"Der Anaesthesist"},{"key":"pone.0245258.ref002","unstructured":"World Health Organization. (2020). Coronavirus disease 2019 (COVID-19): situation report, 195. https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200802-covid-19-sitrep-195.pdf?sfvrsn=5e5da0c5_2 (Retrieved August 3, 2020)"},{"key":"pone.0245258.ref003","author":"AE Gorbalenya","year":"2020","journal-title":"Severe acute respiratory syndrome-related coronavirus: The species and its viruses\u2013a statement of the Coronavirus Study Group"},{"issue":"10228","key":"pone.0245258.ref004","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(20)30419-0","article-title":"A distinct name is needed for the new coronavirus","volume":"395","author":"S Jiang","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"2","key":"pone.0245258.ref005","doi-asserted-by":"crossref","first-page":"W48","DOI":"10.7326\/M20-3862","article-title":"Update alert: should clinicians use chloroquine or hydroxychloroquine alone or in combination with azithromycin for the prophylaxis or treatment of COVID-19? living practice points from the American College of Physicians","volume":"173","author":"A Qaseem","year":"2020","journal-title":"Annals of internal medicine"},{"issue":"24","key":"pone.0245258.ref006","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"J Grein","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"pone.0245258.ref007","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3389\/fphar.2020.01156","article-title":"Rationale for considering oral Idasanutlin as a therapeutic option for COVID-19 patients","volume":"11","author":"G Zauli","year":"2020","journal-title":"Frontiers in Pharmacology"},{"key":"pone.0245258.ref008","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1050-1738(02)00233-5","article-title":"The role of ACE2 in cardiovascular physiology","volume":"13","author":"GY Oudit","year":"2003","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"pone.0245258.ref009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.2162","article-title":"The emerging role of ACE2 in physiology and disease","volume":"212","author":"I Hamming","year":"2007","journal-title":"The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland"},{"issue":"1","key":"pone.0245258.ref010","doi-asserted-by":"crossref","first-page":"e85958","DOI":"10.1371\/journal.pone.0085958","article-title":"Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells","volume":"9","author":"F Xiao","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"pone.0245258.ref011","first-page":"1","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"X Ou","year":"2020","journal-title":"Nature communications"},{"key":"pone.0245258.ref012","doi-asserted-by":"crossref","first-page":"15216","DOI":"10.1038\/ncomms15216","article-title":"Crystal structure of the receptor binding domain of the spike glycoprotein of human betacoronavirus HKU1","volume":"8","author":"X Ou","year":"2017","journal-title":"Nature communications"},{"issue":"6","key":"pone.0245258.ref013","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1128\/JVI.79.6.3289-3296.2005","article-title":"Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents","volume":"79","author":"CT Keng","year":"2005","journal-title":"Journal of virology"},{"key":"pone.0245258.ref014","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","author":"Q Wang","year":"2020","journal-title":"Cell"},{"key":"pone.0245258.ref015","doi-asserted-by":"crossref","first-page":"118105","DOI":"10.1016\/j.lfs.2020.118105","article-title":"An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic","volume":"17","author":"S Jamwal","year":"2020","journal-title":"Life Sciences"},{"issue":"2","key":"pone.0245258.ref016","doi-asserted-by":"crossref","first-page":"fdd-2020","DOI":"10.4155\/fdd-2020-0010","article-title":"Drug repurposing strategies for COVID-19","volume":"2","author":"S. L. Senanayake","year":"2020","journal-title":"Future Drug Discovery"},{"issue":"9","key":"pone.0245258.ref017","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/bioinformatics\/bts139","article-title":"MDWeb and MDMoby: an integrated web-based platform for molecular dynamics simulations","volume":"28","author":"A Hospital","year":"2012","journal-title":"Bioinformatics"},{"issue":"13","key":"pone.0245258.ref018","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014a visualization system for exploratory research and analysis","volume":"25","author":"EF Pettersen","year":"2004","journal-title":"Journal of computational chemistry"},{"issue":"5","key":"pone.0245258.ref019","first-page":"2215","article-title":"Design, synthesis, in-silico study and anticancer potential of novel n-4-piperazinyl-ciprofloxacin-aniline hybrids","volume":"32","author":"R. Akhtar","year":"2019","journal-title":"Pak. J. Pharm. Sci"},{"key":"pone.0245258.ref020","first-page":"275","article-title":"Generalized Born implicit solvent models for biomolecules. Annual review of biophysics","volume":"48","author":"AV Onufriev","year":"2019"},{"issue":"1","key":"pone.0245258.ref021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"W Humphrey","year":"1996","journal-title":"Journal of molecular graphics"},{"issue":"suppl_2","key":"pone.0245258.ref022","doi-asserted-by":"crossref","first-page":"W363","DOI":"10.1093\/nar\/gki481","article-title":"PatchDock and SymmDock: servers for rigid and symmetric docking","volume":"33","author":"D Schneidman-Duhovny","year":"2005","journal-title":"Nucleic acids research"},{"issue":"2","key":"pone.0245258.ref023","doi-asserted-by":"crossref","first-page":"59","DOI":"10.12793\/tcp.2019.27.2.59","article-title":"A review of computational drug repurposing","volume":"27","author":"K Park","year":"2019","journal-title":"Translational and Clinical Pharmacology"},{"issue":"D1","key":"pone.0245258.ref024","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"DS Wishart","year":"2018","journal-title":"Nucleic acids research"},{"key":"pone.0245258.ref025","article-title":"Molecular docking in modern drug discovery: Principles and recent applications","author":"A Sethi","year":"2019","journal-title":"InDrug Discovery and Development-New Advances"},{"issue":"6","key":"pone.0245258.ref026","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","article-title":"Molecular dynamics simulation for all","volume":"99","author":"SA Hollingsworth","year":"2018","journal-title":"Neuron"},{"issue":"8","key":"pone.0245258.ref027","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2174\/1568026618666180531092503","article-title":"Toward small-molecule inhibition of protein\u2013protein interactions: General aspects and recent progress in targeting costimulatory and coinhibitory (immune checkpoint) interactions","volume":"18","author":"D Bojadzic","year":"2018","journal-title":"Current topics in medicinal chemistry"},{"key":"pone.0245258.ref028","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"A Daina","year":"2017","journal-title":"Scientific reports"},{"issue":"D1","key":"pone.0245258.ref029","doi-asserted-by":"crossref","first-page":"D204","DOI":"10.1093\/nar\/gku989","article-title":"UniProt: a hub for protein information","volume":"43","author":"UniProt Consortium","year":"2015","journal-title":"Nucleic acids research"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T19:05:30Z","timestamp":1610132730000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245258"}},"subtitle":[],"editor":[{"given":"Israel","family":"Silman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0245258","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]}}}